← Back to Clinical Trials
Recruiting NCT06183944

NCT06183944 Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06183944
Status Recruiting
Phase
Sponsor Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Condition Pulmonary Embolism
Study Type OBSERVATIONAL
Enrollment 2,500 participants
Start Date 2023-12-11
Primary Completion 2026-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Hierarchical clustering methods

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,500 participants in total. It began in 2023-12-11 with a primary completion date of 2026-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim will be to identify clinically relevant phenotypes in patients with acute pulmonary embolism. Hierarchical clustering methods combined with unsupervised learning (machine learning) will be used to obtain groups of patients who are homogeneous at diagnosis. Evaluating their prognosis at 6 months (recurrence or chronic thromboembolic pulmonary hypertension), account the first 3 months of anticoagulant treatment, would provide an aid to medical decision-making. This research will include a retrospective and a prospective parts. The retrospective part will include patients who have been admitted to CHITS for acute pulmonary embolism since 2019. For the prospective part, it is planned to include patients with same characteristics over the years 2024 and 2025. More than 2,500 patients are expected to be included. This research will have no impact on current patient care. Data from consultations and various examinations carried out as part of care will be collected for six months post-diagnosis in order to meet the research objectives.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years; * Patient with acute pulmonary embolism in CHITS (hospitalised or not). Exclusion Criteria: * Sub-segmental pulmonary embolisms ; * Patient opposition.

Contact & Investigator

Central Contact

Jean-Philippe Suppini

✉ recherche.promotion@ch-toulon.fr

📞 04 94 14 55 25

Principal Investigator

Jean-Noël POGGI, MD

STUDY DIRECTOR

Centre Hospitalier Intercommunal Toulon La Seyne sur Mer

Frequently Asked Questions

Who can join the NCT06183944 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Embolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06183944 currently recruiting?

Yes, NCT06183944 is actively recruiting participants. Contact the research team at recherche.promotion@ch-toulon.fr for enrollment information.

Where is the NCT06183944 trial being conducted?

This trial is being conducted at Toulon, France.

Who is sponsoring the NCT06183944 clinical trial?

NCT06183944 is sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer. The principal investigator is Jean-Noël POGGI, MD at Centre Hospitalier Intercommunal Toulon La Seyne sur Mer. The trial plans to enroll 2,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology